Today's Analyst Stock Ratings | Upgrades, Downgrades

SPY778.57+0.60%QQQ751.38+0.51%BTC/USD83,901.53+0.27%DIA516.21+0.89%GLD384.50+1.55%TLT77.97+0.12%

							Get Alert
Sep 30, 2026	INSMInsmed	$100.60	105.77%	Eliana MerleBarclays 60%	207 237	Previous Overweight Current Overweight	Get Alert
Sep 24, 2026	INSMInsmed	$100.60	86.88%	Andrea NewkirkGoldman Sachs 66%	188	Previous Current Buy	Get Alert
Sep 15, 2026	INSMInsmed	$100.60	96.82%	Adam WalshRoth Capital 27%	198 212	Previous Buy Current Buy	Get Alert
Aug 10, 2026	INSMInsmed	$100.60	73.96%	Jessica FyeJP Morgan 65%	175 179	Previous Overweight Current Overweight	Get Alert
Aug 10, 2026	INSMInsmed	$100.60	93.84%	Danielle BrillTruist Securities 68%	185 195	Previous Buy Current Buy	Get Alert
Aug 7, 2026	INSMInsmed	$100.60	103.78%	Vamil DivanGuggenheim 77%	205 207	Previous Buy Current Buy	Get Alert
Aug 7, 2026	INSMInsmed	$100.60	67.99%	Benjamin BurnettWells Fargo 57%	161 169	Previous Overweight Current Overweight	Get Alert
Aug 7, 2026	INSMInsmed	$100.60	68.99%	Josh SchimmerEvercore ISI Group 68%	160 170	Previous Outperform Current Outperform	Get Alert
Jul 21, 2026	INSMInsmed	$100.60	90.85%	Connor MackayBMO Capital 11%	192	Previous Initiates Current Outperform	Get Alert
Jul 15, 2026	INSMInsmed	$100.60	60.04%	Benjamin BurnettWells Fargo 57%	160 161	Previous Overweight Current Overweight	Get Alert
Jul 10, 2026	INSMInsmed	$100.60	105.77%	Vamil DivanGuggenheim 77%	207 207	Previous Buy Current Buy	Get Alert
Jun 22, 2026	INSMInsmed	$100.60	59.05%	Josh SchimmerEvercore ISI Group 68%	160 162	Previous Outperform Current Outperform	Get Alert
Jun 8, 2026	INSMInsmed	$100.60	77.93%	Jessica FyeJP Morgan 65%	179 180	Previous Overweight Current Overweight	Get Alert
Jun 5, 2026	INSMInsmed	$100.60	93.84%	Leonid TimashevRBC Capital 67%	195 205	Previous Outperform Current Outperform	Get Alert
May 14, 2026	INSMInsmed	$100.60	83.9%	Danielle BrillTruist Securities 68%	185 205	Previous Buy Current Buy	Get Alert
May 8, 2026	INSMInsmed	$100.60	103.78%	Leonid TimashevRBC Capital 67%	205 220	Previous Outperform Current Outperform	Get Alert
May 8, 2026	INSMInsmed	$100.60	59.05%	Benjamin BurnettWells Fargo 57%	160 177	Previous Overweight Current Overweight	Get Alert
May 8, 2026	INSMInsmed	$100.60	124.65%	Vamil DivanGuggenheim 77%	226 230	Previous Buy Current Buy	Get Alert
Apr 17, 2026	INSMInsmed	$100.60	110.74%	Adam WalshRoth Capital 27%	212 212	Previous Buy Current Buy	Get Alert
Apr 14, 2026	INSMInsmed	$100.60	114.71%	Leonid TimashevRBC Capital 67%	212 216	Previous Outperform Current Outperform	Get Alert
Apr 1, 2026	INSMInsmed	$100.60	135.59%	Eliana MerleBarclays 60%	231 237	Previous Overweight Current Overweight	Get Alert
Mar 30, 2026	INSMInsmed	$100.60	110.74%	Matthew HarrisonMorgan Stanley 64%	166 212	Previous Equal-Weight Current Overweight	Get Alert
Mar 26, 2026	INSMInsmed	$100.60	143.54%	Andrew S. FeinHC Wainwright & Co. 55%	230 245	Previous Buy Current Buy	Get Alert
Mar 25, 2026	INSMInsmed	$100.60	104.77%	Graig SuvannavejhMizuho 70%	204 206	Previous Outperform Current Outperform	Get Alert
Mar 24, 2026	INSMInsmed	$100.60	113.72%	Joseph SchwartzLeerink Partners 51%	210 215	Previous Outperform Current Outperform	Get Alert
Mar 24, 2026	INSMInsmed	$100.60	106.76%	Stephen WilleyStifel 72%	205 208	Previous Buy Current Buy	Get Alert
Mar 24, 2026	INSMInsmed	$100.60	75.94%	Benjamin BurnettWells Fargo 57%	175 177	Previous Overweight Current Overweight	Get Alert
Mar 24, 2026	INSMInsmed	$100.60	111.73%	Jason ZemanskyB of A Securities 73%	211 213	Previous Buy Current Buy	Get Alert
Mar 23, 2026	INSMInsmed	$100.60	73.96%	Benjamin BurnettWells Fargo 57%	175 208	Previous Overweight Current Overweight	Get Alert
Mar 16, 2026	INSMInsmed	$100.60	126.64%	Faisal KhurshidJefferies 74%	228	Previous Current Buy	Get Alert
Feb 24, 2026	INSMInsmed	$100.60	102.78%	Graig SuvannavejhMizuho 70%	204 211	Previous Outperform Current Outperform	Get Alert
Feb 23, 2026	INSMInsmed	$100.60	128.63%	Andrew S. FeinHC Wainwright & Co. 55%	230 230	Previous Buy Current Buy	Get Alert
Feb 20, 2026	INSMInsmed	$100.60	106.76%	Benjamin BurnettWells Fargo 57%	208 234	Previous Overweight Current Overweight	Get Alert
Jan 30, 2026	INSMInsmed	$100.60	61.03%	Matthew HarrisonMorgan Stanley 64%	157 162	Previous Equal-Weight Current Equal-Weight	Get Alert
Jan 28, 2026	INSMInsmed	$100.60	129.62%	Eliana MerleBarclays 60%	231	Previous Initiates Current Overweight	Get Alert
Jan 23, 2026	INSMInsmed	$100.60	110.74%	Adam WalshRoth Capital 27%	212	Previous Initiates Current Buy	Get Alert
Jan 21, 2026	INSMInsmed	$100.60	98.81%	Leonid TimashevRBC Capital 67%	197 200	Previous Outperform Current Outperform	Get Alert
Jan 6, 2026	INSMInsmed	$100.60	113.72%	Ashwani VermaUBS 66%	215 223	Previous Buy Current Buy	Get Alert
Dec 18, 2025	INSMInsmed	$100.60	139.56%	Ritu BaralTD Cowen 54%	241 269	Previous Buy Current Buy	Get Alert
Dec 18, 2025	INSMInsmed	$100.60	123.66%	Andrea TanGoldman Sachs 42%	225 258	Previous Buy Current Buy	Get Alert
Dec 18, 2025	INSMInsmed	$100.60	128.63%	Andrew S. FeinHC Wainwright & Co. 55%	230 240	Previous Buy Current Buy	Get Alert
Dec 18, 2025	INSMInsmed	$100.60	119.68%	Vamil DivanGuggenheim 77%	221 230	Previous Buy Current Buy	Get Alert
Dec 18, 2025	INSMInsmed	$100.60	93.84%	Leonid TimashevRBC Capital 67%	195 215	Previous Outperform Current Outperform	Get Alert
Dec 16, 2025	INSMInsmed	$100.60	132.6%	Benjamin BurnettWells Fargo 57%	217 234	Previous Overweight Current Overweight	Get Alert
Dec 16, 2025	INSMInsmed	$100.60	128.63%	Olivia BrayerCantor Fitzgerald 55%	216 230	Previous Overweight Current Overweight	Get Alert
Dec 15, 2025	INSMInsmed	$100.60	156.46%	Andrea TanGoldman Sachs 42%	225 258	Previous Buy Current Buy	Get Alert
Dec 11, 2025	INSMInsmed	$100.60	167.4%	Ritu BaralTD Cowen 54%	231 269	Previous Buy Current Buy	Get Alert
Dec 1, 2025	INSMInsmed	$100.60	154.47%	Graig SuvannavejhMizuho 70%	196 256	Previous Outperform Current Outperform	Get Alert
Nov 20, 2025	INSMInsmed	$100.60	129.62%	Ritu BaralTD Cowen 54%	223 231	Previous Buy Current Buy	Get Alert
Oct 31, 2025	INSMInsmed	$100.60	115.71%	Tiago FauthWells Fargo 58%	171 217	Previous Overweight Current Overweight	Get Alert
Oct 31, 2025	INSMInsmed	$100.60	123.66%	Andrea TanGoldman Sachs 42%	196 225	Previous Buy Current Buy	Get Alert
Oct 31, 2025	INSMInsmed	$100.60	121.67%	Trung HuynhUBS 72%	194 223	Previous Buy Current Buy	Get Alert
Oct 31, 2025	INSMInsmed	$100.60	113.72%	Leonid TimashevRBC Capital 67%	139 215	Previous Outperform Current Outperform	Get Alert
Oct 27, 2025	INSMInsmed	$100.60	85.88%	Jason ZemanskyB of A Securities 73%	142 187	Previous Buy Current Buy	Get Alert
Oct 14, 2025	INSMInsmed	$100.60	92.84%	Trung HuynhUBS 72%	140 194	Previous Buy Current Buy	Get Alert
Oct 3, 2025	INSMInsmed	$100.60	94.83%	Andrea TanGoldman Sachs 42%	121 196	Previous Buy Current Buy	Get Alert
Oct 2, 2025	INSMInsmed	$100.60	91.85%	Ritu BaralTD Cowen 54%	154 193	Previous Buy Current Buy	Get Alert
Sep 8, 2025	INSMInsmed	$100.60	70.97%	Vamil DivanGuggenheim 77%	125 172	Previous Buy Current Buy	Get Alert
Sep 3, 2025	INSMInsmed	$100.60	69.98%	Tiago FauthWells Fargo 58%	140 171	Previous Overweight Current Overweight	Get Alert
Aug 21, 2025	INSMInsmed	$100.60	43.14%	Maxwell SkorMorgan Stanley 55%	126 144	Previous Equal-Weight Current Equal-Weight	Get Alert
Aug 20, 2025	INSMInsmed	$100.60	34.19%	Jessica FyeJP Morgan 65%	111 135	Previous Overweight Current Overweight	Get Alert
Aug 20, 2025	INSMInsmed	$100.60	—	Matt PhippsWilliam Blair 45%	—	Previous Initiates Current Outperform	Get Alert
Aug 14, 2025	INSMInsmed	$100.60	38.17%	Nicole GerminoTruist Securities 69%	126 139	Previous Buy Current Buy	Get Alert
Aug 14, 2025	INSMInsmed	$100.60	44.14%	Stephen WilleyStifel 72%	121 145	Previous Buy Current Buy	Get Alert
Aug 13, 2025	INSMInsmed	$100.60	25.25%	Matthew HarrisonMorgan Stanley 64%	112 126	Previous Overweight Current Equal-Weight	Get Alert
Aug 13, 2025	INSMInsmed	$100.60	138.57%	Andrew S. FeinHC Wainwright & Co. 55%	120 240	Previous Buy Current Buy	Get Alert
Aug 13, 2025	INSMInsmed	$100.60	39.17%	Trung HuynhUBS 72%	133 140	Previous Buy Current Buy	Get Alert
Aug 13, 2025	INSMInsmed	$100.60	37.18%	Leonid TimashevRBC Capital 67%	120 138	Previous Outperform Current Outperform	Get Alert
Aug 13, 2025	INSMInsmed	$100.60	41.15%	Andrea TanGoldman Sachs 42%	114 142	Previous Buy Current Buy	Get Alert
Aug 13, 2025	INSMInsmed	$100.60	64.02%	Graig SuvannavejhMizuho 70%	130 165	Previous Outperform Current Outperform	Get Alert
Aug 13, 2025	INSMInsmed	$100.60	47.12%	Kelly ShiJefferies 55%	129 148	Previous Buy Current Buy	Get Alert
Aug 12, 2025	INSMInsmed	$100.60	39.17%	Tiago FauthWells Fargo 58%	130 140	Previous Overweight Current Overweight	Get Alert
Aug 8, 2025	INSMInsmed	$100.60	19.28%	Leonid TimashevRBC Capital 67%	108 120	Previous Outperform Current Outperform	Get Alert
Aug 8, 2025	INSMInsmed	$100.60	32.21%	Trung HuynhUBS 72%	124 133	Previous Buy Current Buy	Get Alert
Jul 22, 2025	INSMInsmed	$100.60	29.22%	Tiago FauthWells Fargo 58%	119 130	Previous Overweight Current Overweight	Get Alert
Jul 17, 2025	INSMInsmed	$100.60	7.36%	Matthew HarrisonMorgan Stanley 64%	102 108	Previous Overweight Current Overweight	Get Alert
Jul 8, 2025	INSMInsmed	$100.60	10.34%	Jessica FyeJP Morgan 65%	90 111	Previous Overweight Current Overweight	Get Alert
Jun 11, 2025	INSMInsmed	$100.60	9.34%	Stephen WilleyStifel 72%	92 110	Previous Buy Current Buy	Get Alert
Jun 11, 2025	INSMInsmed	$100.60	11.33%	Andrea TanGoldman Sachs 42%	100 112	Previous Buy Current Buy	Get Alert
Jun 11, 2025	INSMInsmed	$100.60	9.34%	Graig SuvannavejhMizuho 70%	96 110	Previous Outperform Current Outperform	Get Alert
Jun 11, 2025	INSMInsmed	$100.60	5.37%	Leonid TimashevRBC Capital 67%	99 106	Previous Outperform Current Outperform	Get Alert
Jun 11, 2025	INSMInsmed	$100.60	1.39%	Matthew HarrisonMorgan Stanley 64%	90 102	Previous Overweight Current Overweight	Get Alert
Jun 11, 2025	INSMInsmed	$100.60	8.35%	Jason ZemanskyB of A Securities 73%	94 109	Previous Buy Current Buy	Get Alert
Jun 11, 2025	INSMInsmed	$100.60	18.29%	Tiago FauthWells Fargo 58%	107 119	Previous Overweight Current Overweight	Get Alert
Jun 11, 2025	INSMInsmed	$100.60	19.28%	Andrew FeinHC Wainwright & Co. 74%	90 120	Previous Buy Current Buy	Get Alert
Jun 10, 2025	INSMInsmed	$100.60	7.36%	Nicole GerminoTruist Securities 69%	108 108	Previous Buy Current Buy	Get Alert
Jun 10, 2025	INSMInsmed	$100.60	14.31%	Joseph SchwartzLeerink Partners 51%	100 115	Previous Outperform Current Outperform	Get Alert
May 13, 2025	INSMInsmed	$100.60	4.37%	Kelly ShiJefferies 55%	105	Previous Initiates Current Buy	Get Alert
May 9, 2025	INSMInsmed	$100.60	8.35%	Trung HuynhUBS 72%	109 110	Previous Buy Current Buy	Get Alert
Apr 22, 2025	INSMInsmed	$100.60	-10.54%	Andrew FeinHC Wainwright & Co. 74%	90 90	Previous Buy Current Buy	Get Alert
Mar 20, 2025	INSMInsmed	$100.60	-4.57%	Jason ZemanskyB of A Securities 73%	92 96	Previous Buy Current Buy	Get Alert
Mar 19, 2025	INSMInsmed	$100.60	-0.6%	Leonid TimashevRBC Capital 67%	100 100	Previous Outperform Current Outperform	Get Alert
Mar 6, 2025	INSMInsmed	$100.60	9.34%	Trung HuynhUBS 72%	105 110	Previous Buy Current Buy	Get Alert
Feb 25, 2025	INSMInsmed	$100.60	-0.6%	Leonid TimashevRBC Capital 67%	100	Previous Initiates Current Outperform	Get Alert
Feb 25, 2025	INSMInsmed	$100.60	0.4%	Vamil DivanGuggenheim 77%	101 101	Previous Buy Current Buy	Get Alert
Feb 24, 2025	INSMInsmed	$100.60	-10.54%	Andrew FeinHC Wainwright & Co. 74%	90 90	Previous Buy Current Buy	Get Alert
Feb 21, 2025	INSMInsmed	$100.60	7.36%	Nicole GerminoTruist Securities 69%	105 108	Previous Buy Current Buy	Get Alert
Feb 21, 2025	INSMInsmed	$100.60	-4.57%	Stephen WilleyStifel 72%	96 97	Previous Buy Current Buy	Get Alert
Feb 21, 2025	INSMInsmed	$100.60	-10.54%	Andrew FeinHC Wainwright & Co. 74%	90 90	Previous Buy Current Buy	Get Alert
Feb 20, 2025	INSMInsmed	$100.60	—	Jennifer KimCantor Fitzgerald 70%	—	Previous Overweight Current Overweight	Get Alert

Recent Analyst Stock Rating News

PRO

William Blair Downgrades Alignment Healthcare to Market Perform

William Blair analyst Ryan Daniels downgrades Alignment Healthcare (NASDAQ:ALHC) from Outperform to Market Perform.

PRO

UBS Upgrades ArcelorMittal to Buy

UBS analyst Andrew Jones upgrades ArcelorMittal (NYSE:MT) from Neutral to Buy.

PRO

Citigroup Maintains Buy on Sunrun, Lowers Price Target to $14

Citigroup analyst Vikram Bagri maintains Sunrun (NASDAQ:RUN) with a Buy and lowers the price target from $16 to $14.

PRO

Citigroup Maintains Buy on Viper Energy, Lowers Price Target to $52

Citigroup analyst Paul Diamond maintains Viper Energy (NASDAQ:VNOM) with a Buy and lowers the price target from $57 to $52.

PRO

Citigroup Maintains Neutral on PepsiCo, Lowers Price Target to $135

Citigroup analyst Filippo Falorni maintains PepsiCo (NASDAQ:PEP) with a Neutral and lowers the price target from $142 to $135.

PRO

Citigroup Maintains Buy on Kodiak Gas Services, Lowers Price Target to $82

Citigroup analyst Douglas Irwin maintains Kodiak Gas Services (NYSE:KGS) with a Buy and lowers the price target from $86 to $82.

PRO

Citigroup Downgrades Pershing Square to Sell, Maintains Price Target to $45

Citigroup analyst Matthew Heimermann downgrades Pershing Square (NYSE:PS) from Neutral to Sell and maintains the price target from $45 to $45.

PRO

Citigroup Initiates Coverage On Fortune Brands with Buy Rating, Announces Price Target of $48

Citigroup analyst Anthony Pettinari initiates coverage on Fortune Brands (NYSE:FBIN) with a Buy rating and announces Price Target of $48.

PRO

Maxim Group Initiates Coverage On The RMR Group with Buy Rating, Announces Price Target of $26

Maxim Group analyst Michael Diana initiates coverage on The RMR Group (NASDAQ:RMR) with a Buy rating and announces Price Target of $26.

PRO

JP Morgan Maintains Neutral on Steel Dynamics, Lowers Price Target to $260

JP Morgan analyst Bill Peterson maintains Steel Dynamics (NASDAQ:STLD) with a Neutral and lowers the price target from $272 to $260.

The Best Trading Research Platform

For Retail Investors and Professional Trades Alike.

Get Started for Free

What Are Analyst Stock Ratings?

Analyst ratings measure the expected performance of a stock during a given time period. Analysts and brokerage firms often use ratings when they issue stock recommendations to stock traders.

Analysts arrive at stock ratings after they research companies’ public financial statements, communicate with executives and customers and interact with companies in other ways.

Most analysts issue ratings 4 times a year, usually at 3-month intervals.

How to Use Analyst Ratings

As an investor or trader, you want to be able to use analyst ratings effectively. Here are steps you can take to understand how to synthesize all the information analysts report about a particular company and how to apply it to your own trades.

Step 1: Check Ratings History

In the short term, look to see whether analysts suggest an initiation, upgrade or downgrade for a particular stock. Understand how the rating changed compared to the previous rating and whether a price target gets announced or changed.

Sometimes the rating stays the same and only the price target changes, which could cause the stock to move in either direction, depending on the significance of the change between the 2 price targets.

Step 2: Check for Other News

In the short term, check to see how the stock reacts to positive or negative news. This will be an indication of the company’s outlook because analyst ratings usually come out after the company announces news (it’ll typically be earnings news).

Step 3: Look at the Sector for News

Check to see if other stocks in the sector also received similar ratings. This could indicate micro news, which refers to when the whole sector or specific company trades in a specific way due to news outside of one company.

Step 4: Look at the Note

If available, look over the analyst note itself. The beginning of the note has the main information of the rating and price target. Investors should also take a look at the summary of the note, which you can find in the first couple pages and give you a concrete overview of the company. This can help you get an understanding of how analysts arrived at their thesis on the stock.

An example of an analyst note. Source: Needham

Step 5: Make a Decision

After reviewing the analyst ratings (and whether the analyst proposes a change or initiation) and find the reason for that note. Make a decision based on the analyst thesis on the company. This should give you guidance on how to make your thesis. Analyst ratings are a good indication of what professionals believe the company or sector will do, helping you get a better understanding of the companies you’re interested in.

Analyst Rating Accuracy

Analyst ratings are not set in stone and nobody knows indefinitely what a stock will do. Therefore, analyst ratings should be taken as an educated guess made by professionals who carefully study the specific company and sector in question. It's not a surprise that the accuracy of each rating can vary by each individual analyst and specific ratings on companies.

In other words, there’s no hard number or percentage on how accurate analyst ratings are because they are like educated guesses on what they think the stock will do based on their research, within that particular sector. In addition, each firm has so many analysts and so many different companies to review that you can compare ratings to glean what you believe is the truth.

Where Analyst Ratings Come From

Analyst ratings come from stock analysts. Analysts “go deep” on companies within a particular industry or sector. Some analysts employ a top-down approach (they start with an industry or sector and look for excellent companies within that industry or sector) and other stock analysts choose a bottom-up approach, which means they start with the company first and connect the dots within that company’s sector or industry. Analysts evaluate:

Financial statements
Economic fundamentals
Suppliers, customers and competitors
Management quality
Business model
Revenue
Expenses
Assets
Liabilities

While these evaluations are done using facts and figures that any investor can access, they come down to a conclusion the analyst must draw. While this isn’t an unqualified opinion, analysts will disagree because their interpretations of the data could vary.

Types of Stock Ratings

Stock ratings can range from simple “buy” and “sell” ratings to “equal weight” and “outperform” ratings. Here’s a quick overview of how analysts rate stocks.

Buy Rating

A “buy” rating indicates that an analyst is optimistic about a stock’s short-term or mid-term growth and recommends that traders purchase the stock. An analyst may even go so far as to indicate that a stock is a “strong buy.” At the same time, you may choose to swing trade the asset for a profit and come back later to start the process all over again.

Sell Rating

A “sell” rating means that an analyst believes the stock will trend downward in a particular time frame. Analysts might even refer to a security as a “strong sell.” Remember, though, you may want to swing trade and come back to this asset in the future even though you just chose to sell, just as you would under a “buy” rating.

Hold

A “hold” rating suggests that investors should not buy more of or sell the specified stock because they believe the stock should perform in a way that’s consistent with the market or will perform similarly to comparable companies within that particular sector. This is akin to the value investing approach that Warren Buffett uses, looking to gain long-term value from a single stock rather than flipping it because of a bad week. As many have said, it’s not a loss until you sell.

Underperform

An “underperform” rating means an analyst indicates that a stock is expected to perform below the market or sector average. And yes, while the underperform rating may not bode well for an asset in the next few weeks, it may not stay that way. Continue to carefully monitor your portfolio to ensure that an underperforming asset hasn’t turned itself around. As companies are faced with the Herculean task of pleasing shareholders, they will push to fix their underperforming stocks, meaning that a stock you wrote off could rise again.

Outperform

An “outperform” rating means that an analyst expects a stock to outperform the market or sector average. While the stock may look to outperform the market or a sector’s average, that doesn’t mean it will continue to soar forever. You must look at an outperform rating as what that asset will do in recent times, but it may not maintain that trajectory.

Equal-Weight

An equal weight rating means that an analyst believes that an individual stock's performance will tie to the average of all the stocks that an analyst covers in that particular sector. This type of rating helps investors get a true comparison of stocks to each other within a particular sector or industry. At the same time, equal-weight ratings could change at any time.

Price Target

A price target is an analyst’s projection of a stock’s future price. A price target is generally set up in a general trade or area where the asset might land. This means that the analyst could get close without hitting the figure on the head. Even so, the analyst wants to get close and better predict the movement of the marketplace and the asset.

Understanding Stock Ratings

Stock ratings are assessments of the investment potential of a particular stock. They are typically created by financial analysts who evaluate a company's financial performance, competitive positioning, and market outlook to provide guidance on the stock's expected future performance.

Ratings typically range from "buy" to "sell," with variations in between, such as "hold," "accumulate," or "neutral." A "buy" rating suggests that the stock is likely to perform well in the future, and investors should consider purchasing it. Conversely, a "sell" rating indicates that the stock is expected to underperform, and investors should consider selling it.

It's important to note that ratings are not guarantees of performance and should not be relied upon solely when making investment decisions. Ratings are just one factor to consider when evaluating a stock's potential, and investors should also conduct their own research and analysis to make informed decisions.

Another thing to keep in mind is that different analysts may have different opinions on a stock, so it's a good idea to consider multiple ratings before making an investment decision.

In addition to analyst ratings, investors can also consider other factors when evaluating a stock, such as its financial statements, management team, industry trends, and overall market conditions. By combining all of these factors, investors can make informed decisions about which stocks to buy or sell.

In summary, stock ratings are an important tool for investors to consider when evaluating a stock's potential, but they should not be the only factor used in investment decision-making. It's important to conduct your own research, consider multiple ratings, and take into account other factors before making an investment decision.

Should You Use Analyst Ratings to Inform Your Own Trades?

You can definitely use analyst ratings to inform your own trades and inform your own thesis but it’s a good idea to do your own research. However, analyst ratings are just one step in what should be a much larger investment strategy. Don’t fall in love with just one analyst. Compare notes. Look into how these ratings match with activity on the market and current events. Plus, remember that an analyst rating could easily be incorrect. No one is perfect, but these ratings are a good place to start.

Visit Benzinga News for more guidance on how to research companies and make decisions about research, trading and investing.

Compare Online Stock Brokers

Claim Exclusive Offers

Interactive Brokers Review
Good Fit For:
Active and Global Traders
VIEW PROS & CONS:
Securely through Interactive Brokers’ website
Plus500 Review
Good Fit For:
Leveraged Trading
VIEW PROS & CONS:
securely through Plus500 Yield's website
public.com Review
Good Fit For:
Trading Ideas
VIEW PROS & CONS:
securely through public.com's website
Robinhood Review
Good Fit For:
Commission-Free Mobile Trading
VIEW PROS & CONS:
securely through Robinhood's website
TradeZero Review
Good Fit For:
Active Short Sellers
VIEW PROS & CONS:
securely through TradeZero [SPONSORED]'s website